http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-08-23T10:06:13.772Z

http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

"Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4.1) Women who are pregnant or may become pregnant (4.3) Nursing mothers (4.4). Hypersensitivity to any component of this medication (4.2) Active liver disease which may include unexplained persistent elevations of hepatic transaminase levels Hypersensitivity to any component of this medication Women who are pregnant or may become pregnant. Atorvastatin calcium may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of atorvastatin calcium use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. ATORVASTATIN CALCIUM SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, atorvastatin calcium should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1 ) It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require atorvastatin calcium treatment should not breastfeed their infants [see Use in Specific Populations (8.3)"

Leoni Bücken

2021-08-23T10:06:13.772Z

http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_409 DOID_409

Leoni Bücken

2021-08-23T10:06:13.772Z

http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-08-23T10:06:13.772Z

http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB01076 drugbank:DB01076

Leoni Bücken

2021-08-23T10:06:13.772Z

http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-08-23T10:06:13.772Z

http://purl.org/np/RA3HAU7gjq... RA3HAU7gjq

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/MedicalContraindication MedicalContraindication

Leoni Bücken

2021-08-23T10:06:13.772Z